Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Successful Desensitization of a Patient With Cetuximab Hypersensitivity: A Case Report Publisher Pubmed



Solduzian M1 ; Anvari S2 ; Taghvaye Masoumi H1 ; Shahi F3 ; Jahangardrafsanjani Z1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran
  3. 3. Department of Hematology and Medical Oncology, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Tehran, Iran

Source: Journal of Oncology Pharmacy Practice Published:2019


Abstract

Background: Severe hypersensitivity reaction is a dangerous adverse drug reaction in patients receiving cetuximab. It requires drug discontinuation and medical management. Case description: A 48-year-old man, previously diagnosed with metastatic colorectal cancer, was admitted for therapy continuation. During the first infusion of cetuximab, the patient experienced acute signs of hypersensitivity reactions. The treatment team decided to administer cetuximab employing the desensitization protocol. Conclusions: This study reports a severe hypersensitivity reaction to cetuximab in an adult patient with colorectal cancer. This patient was successfully managed with a new safe and rapid desensitization protocol. © The Author(s) 2018.
Related Docs
1. A Comprehensive Review of Clinical Trials on Egfr Inhibitors Such As Cetuximab and Panitumumab As Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer, Avicenna Journal of Medical Biotechnology (2015)
2. Asthma and Allergy, Clinical Immunology (2022)
Experts (# of related papers)
View all Related Experts
Shekoufeh Nikfar (1)
Nima Rezaei (1)